Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying
Information source: Profil Institut für Stoffwechselforschung GmbH
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Mellitus
Intervention: Luyxumia versus Lantus (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Profil Institut für Stoffwechselforschung GmbH
Summary
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion
and gastric emptying
Clinical Details
Official title: A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Primary outcome: AUCISEC(0-10min)
Detailed description:
Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion
and gastric emptying
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with type 2 diabetes mellitus diagnosed at least one year before the
screening visit not previously treated with glitazones, insulin or GLP-1 agonists
- Inadequately controlled diabetes mellitus
Exclusion Criteria:
- Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or
secondary forms of diabetes such as due to pancreatitis
Locations and Contacts
St. Josef-Hospital, University Hospital, Ruhr, Bochum 44791, Germany
Profil Institut für Stoffwechselforschung GmbH, Neuss 41460, Germany
Additional Information
Starting date: December 2013
Last updated: January 21, 2015
|
